Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00878709 · ClinicalTrials.gov registry record · Phase 3
Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer
A Phase 3 study, sponsored by Puma Biotechnology.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,840
- Enrollment target
NCT00878709 is a Phase 3 study that has completed, run by Puma Biotechnology. The registered enrollment target is 2,840 participants.
The verdict
NCT00878709, a Phase 3 study, has completed, sponsored by Puma Biotechnology.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,840 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate whether neratinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab.
Interventions
- OTHER placebo
- DRUG neratinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,840 participants |
| Start Date | 2009-07-09 |
| Est. Completion | 2019-10-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00878709
The ClinicalTrials.gov registry entry for NCT00878709 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,840 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Puma Biotechnology, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00878709 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00878709 about?
NCT00878709 is a clinical study titled "Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer". The purpose of this study is to investigate whether neratinib can further reduce the risk of recurrence from previously diagnosed HER-2 positive breast cancer after adjuvant treatment with trastuzumab.
What is the current status of trial NCT00878709?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,840 participants. The study started on 2009-07-09. Estimated completion is 2019-10-04.
What interventions are being tested in trial NCT00878709?
The interventions under investigation include: placebo (OTHER), neratinib (DRUG).
Who is sponsoring clinical trial NCT00878709?
This trial is sponsored by Puma Biotechnology, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.